First Experiences with
177Lu
PSMA
olaparib
pembrolizumab
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
30
06
2020
accepted:
30
10
2020
pubmed:
29
11
2020
medline:
6
1
2022
entrez:
28
11
2020
Statut:
ppublish
Résumé
Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with
Identifiants
pubmed: 33246977
pii: jnumed.120.249029
doi: 10.2967/jnumed.120.249029
pmc: PMC8882875
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Phthalazines
0
Piperazines
0
pembrolizumab
DPT0O3T46P
Prostate-Specific Antigen
EC 3.4.21.77
olaparib
WOH1JD9AR8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-978Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Nat Rev Genet. 2006 Jan;7(1):45-54
pubmed: 16369571
Mol Imaging Biol. 2015 Aug;17(4):565-74
pubmed: 25896814
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Clin Cancer Res. 2020 Jun 15;26(12):2774-2776
pubmed: 32253231
Cancer Imaging. 2019 Jun 11;19(1):37
pubmed: 31186052
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
Prostate. 2018 Aug;78(11):775-789
pubmed: 29717499
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Diagnostics (Basel). 2013 Oct 02;3(4):344-55
pubmed: 26824927
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
Trends Genet. 2000 Jun;16(6):259-64
pubmed: 10827453
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890